Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results

Treatment for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer


Title

Breast Cancer - Treatment for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Therapeutic Area
Principal Investigator John Erban, MD
Min Age 18 Years
Gender Female
Contact Jennifer Caplain, RN
617-636-9161
More Information http://www.clinicaltrials.gov/

Overview

This study is being done to find out if a combination of just two chemotherapy drugs, docetaxel and cyclophosphamide, is as good as using different combinations of the chemotherapy drugs doxorubicin and cyclophosphamide, given with either docetaxel or paclitaxel, in fighting against your type of breast cancer.

Study Details

Inclusion Criteria

  • Participants must have unilateral invasive adenocarcinoma of the breast 
  • Participants must have undergone either a total mastectomy or breast-conserving surgery (lumpectomy).

Exclusion Criteria

  • Participants must not have T4 tumors including inflammatory breast cancer. 
  • Participants must not have any history of ipsilateral invasive breast cancer or ipsilateral DCIS. 
  • Participants must not have had previous therapy with anthracyclines or taxanes for any malignancy

Study Requirements

Participants will be randomized into one of the two groups. If you are in group 1, you  will take a combination and schedule of three chemotherapy drugs (doxorubicin, cyclophosphamide with either docetaxel or paclitaxel) that you and your doctor choose. If you are in group 2, you will take a combination of the chemotherapy drugs docetaxel and cyclophosphamide. You will have physical exams, blood work, Mammogram, and other scans per study protocol.
Nurse navigators for cancer patients at Tufts Medical Center.

Are you interested in learning more about this clinical trial?

Send us a message and we'll get back to you with more information.

Request information